Does Bactrim Cover Enterococcus?
No, Bactrim (trimethoprim-sulfamethoxazole) does NOT provide reliable coverage against Enterococcus species and should not be used to treat enterococcal infections, despite appearing susceptible on standard in vitro testing.
The Critical Problem: In Vitro vs. In Vivo Discordance
The FDA-approved indications for Bactrim explicitly list coverage for E. coli, Klebsiella, Enterobacter, Proteus, Shigella, H. influenzae, S. pneumoniae, and P. jirovecii—but notably Enterococcus is completely absent from this list 1.
This omission is not accidental. Enterococci possess a unique ability to incorporate exogenous folates from their environment, which completely bypasses the antifolate mechanism of trimethoprim-sulfamethoxazole 2, 3. While standard laboratory susceptibility testing may show enterococci as "susceptible" (because testing media lacks folates), this creates a dangerous false impression.
Clinical Evidence of Treatment Failure
The real-world consequences are severe:
- Case reports document patients developing enterococcal bacteremia while on TMP-SMX for UTI, despite isolates appearing susceptible in vitro 3
- In a mouse model of lethal enterococcal peritonitis, mortality was 95% with TMP-SMX versus 40% with ampicillin, despite adequate drug levels in serum and peritoneal fluid 4
- When susceptibility testing is performed in media containing fresh urine (mimicking the in vivo environment), MICs increase 360-fold compared to standard media 2
Why Standard Testing Misleads Clinicians
Standard Mueller-Hinton broth used in susceptibility testing is deliberately depleted of folates to allow trimethoprim to work. However, in the human body—particularly in urine, blood, and tissues—folates are abundant. Enterococci simply absorb these environmental folates and continue synthesizing nucleic acids, rendering TMP-SMX ineffective 2, 3.
Even studies showing low MICs in folate-free media demonstrate that TMP-SMX fails to achieve consistent bactericidal activity against enterococci 5.
Regulatory and Expert Consensus
The European Committee on Antimicrobial Susceptibility Testing (EUCAST) has addressed this issue by categorizing wild-type enterococci as intermediate to trimethoprim/sulfamethoxazole, specifically to prevent clinicians from being misled by standard susceptibility reports 2.
What to Use Instead
For enterococcal infections, appropriate coverage includes:
- Ampicillin (first-line for susceptible strains)
- Vancomycin (for ampicillin-resistant strains)
- Combination therapy with aminoglycosides for synergy in serious infections like endocarditis
Guidelines for intra-abdominal infections specifically recommend adding ampicillin to regimens (like ceftriaxone-metronidazole) that would otherwise lack enterococcal coverage 6.
Clinical Pitfall to Avoid
Do not rely on susceptibility reports showing enterococci as "susceptible" to TMP-SMX. Clinical microbiology laboratories reporting such susceptibilities are providing misleading and potentially dangerous information 3. If you receive such a report, contact the laboratory to clarify and request appropriate susceptibility testing for penicillins or vancomycin.